Systems immunology-based drug repurposing framework to target inflammation in atherosclerosis [Tissue_RNA-seq]

we present a novel path to drug repurposing to identify new immunotherapies for ASCVD. The integration of time of-flight mass cytometry (CyTOF) and RNA-sequencing identified unique inflammatory signatures in peripheral blood mononuclear cells (PBMCs) stimulated with ASCVD plasma. By comparing these inflammatory signatures to large-scale gene expression data from the LINCS L1000 dataset, we identified drugs that could reverse this inflammatory response. In conclusion, a systems immunology-driven drug repurposing with pre- clinical validation strategy can aid the development of new cardiovascular immunotherapies. Comparative gene expression profiling analysis of RNA-seq data for atherosclerotic patient tissue stimulated with autologous plasma -/+ saracatinib was performed.